COMPOUND PROFILE / SMALL MOLECULES
Anamorelin.
Research draftAnamorelin is an oral ghrelin-receptor agonist investigated for cancer-associated cachexia.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
Anamorelin is an oral ghrelin-receptor agonist investigated for cancer-associated cachexia.
Mechanism
It affects appetite and endocrine pathways relevant to lean mass.
Human research
Randomised cancer trials measured appetite, weight and body-composition outcomes. Lean-mass changes do not guarantee improved strength.
Preclinical & other research
Animal work supports an appetite and metabolic rationale.
Safety & unknowns
Glucose, cardiac and other product-specific risks need the relevant prescribing information.
Regulatory status
Medical use is jurisdiction-specific; Japanese authorisation does not imply universal approval or enhancement eligibility.
Reported use & evidence
The supplied Anamorelin profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.